The COVID-19 pandemic has mainstreamed wastewater-based epidemiology, which analyzes sewage to detect disease outbreaks. Biobot Analytics can identify current community levels of disease and opioid use from just 150 ml of an aggregate sewage sample from a 24-hour period. Because samples include everyone in a sewage system, “there’s an incredible amount of intelligence in wastewater,” says Newsha Ghaeli, Biobot’s president and co-founder. The company is the first to commercialize data from sewage. The CDC in September expanded Biobot’s contract to include monkeypox monitoring.
More Must-Reads From TIME
- Inside One Indian iPhone Factory
- Congress Avoided a Shutdown. What Happens Next?
- Global Climate Solutions Exist. It's Time to Deploy Them
- What Happens to Diane Feinstein's Senate Seat
- The Enduring Charm of John Grisham
- Who The Golden Bachelor Leaves Out
- Kerry Washington: The Story of My Abortion
- Want Weekly Recs on What to Watch, Read, and More? Sign Up for Worth Your Time
